No sabemos si la última respuesta a esta solicitud contiene información o no – si eres Olivier Hoedeman por favor abre una sesión y háznoslo saber.

The Vaccines Procurement Steering Committee & the Joint Negotiation Team

Estamos a la espera de que Olivier Hoedeman lea las últimas respuestas y de que actualice el estado.

Dear Secretariat General,

Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I am requesting documents which contain the following information:

- all reports (and other notes) from meetings of the Vaccines Procurement Steering Committee and the Joint Negotiation Team (JNT) with representatives of pharmaceutical companies about Advance Purchase Agreements (APAs) and the purchase of potential vaccines against COVID-19.

- all correspondence (including emails and their attachments) between the Vaccines Procurement Steering Committee and the Joint Negotiation Team (JNT) and representatives of pharmaceutical companies (including Sanofi-GSK, Johnson & Johnson, CureVac, AstraZeneca, Moderna and others) about Advance Purchase Agreements (APAs) and the purchase of potential vaccines against COVID-19.

- a list of all the above-mentioned documents (including dates, names of participants/senders/recipients and their affiliation, subject of meeting/correspondence).

There is a clear public interest in disclosure of these documents. The transparency rules as set out in the Lisbon Treaty oblige the EU institutions to work as openly and as closely as possible to citizens. There is clearly a lot at stake for EU citizens in the vaccine deal negotiations. Citizens have the right to know about these negotiations that are happening on their behalf, involving billions of euros of public money to be spent for the development of vaccines.

Secrecy around the negotiations about the vaccines, moreover, may undermine public confidence in the EU and its handling of the pandemic, but also in the vaccines themselves (with negative consequences for public health beyond the current pandemic).

Blanket confidentiality cannot be the rule for the negotiations about the Covid19 vaccine contracts. Price and other sorts of confidentiality covering commercial aspects of these contracts cannot preclude transparency, for instance around negotiations about liability and other provisions with clear implications for patient safety and the protection of public health.

The currently negotiated contracts for potential covid19 vaccines differ from usual medicines procurement deals. Considerable amounts of public money and public guarantees are invested into the R&D and manufacturing process through the signature of advance purchase agreements between the European Commission and individual pharma companies. APAs essentially constitute insurance policies paid for by taxpayers' money which amongst other guarantee losses sustained by pharma developers. Governments commit in advance to shouldering the cost of certain liabilities sustained by pharma companies throughout the R&D process; by doing so they de-risk it and become co-developers. This makes the need for transparency and public accountability around the negotiations even stronger.

Please note that there is also a clear public interest in the release of the names of the members of the Joint Negotiation Team (JNT). The public has the right to know who is negotiating on the EU’s behalf. Knowing the names of the negotiators is a pre-condition for assessing potential conflicts of interest.

Yours sincerely,

Olivier Hoedeman
on behalf of Corporate Europe Observatory (CEO)
Rue d'Edimbourg 26,
1050 Brussels, Belgium
Tel. +32 (0)2 893 0930

Secretaría General de la Comisión Europea

Your message has been received by the Transparency Unit of the
Secretariat-General of the European Commission.
Requests for public access to documents are treated on the basis of
[1]Regulation (EC) No 1049/2001 of 30 May 2001 regarding public access to
European Parliament, Council and Commission documents.
The Secretariat-General will reply to your request within 15 working days
upon registration of your request and will duly inform you of the
registration of the request (or of any additional information to be
provided in view of its registration and/or treatment).
 
 
L’unité «Transparence» du secrétariat général de la Commission européenne
a bien reçu votre message.
Les demandes d’accès du public aux documents sont traitées sur la base du
[2]règlement (CE) n° 1049/2001 du 30 mai 2001 relatif à l’accès du public
aux documents du Parlement européen, du Conseil et de la Commission.
Le secrétariat général répondra à votre demande dans un délai de 15 jours
ouvrables à compter de la date d’enregistrement de votre demande, et vous
informera de cet enregistrement (ou vous indiquera toute information
supplémentaire à fournir en vue de l'enregistrement et/ou du traitement de
votre demande).
 
 
Ihre Nachricht ist beim Referat „Transparenz“ des Generalsekretariats der
Europäischen Kommission eingegangen.
Anträge auf Zugang zu Dokumenten werden auf der Grundlage der
[3]Verordnung (EG) Nr. 1049/2001 vom 30. Mai 2001 über den Zugang der
Öffentlichkeit zu Dokumenten des Europäischen Parlaments, des Rates und
der Kommission behandelt.
Das Generalsekretariat beantwortet Ihre Anfrage innerhalb von
15 Arbeitstagen nach deren Registrierung und wird Sie über die
Registrierung Ihres Antrags (oder die Notwendigkeit weiterer Informationen
im Hinblick auf dessen Registrierung und/oder Bearbeitung) unterrichten.
 
 

References

Visible links
1. https://eur-lex.europa.eu/legal-content/...
2. https://eur-lex.europa.eu/legal-content/...
3. https://eur-lex.europa.eu/legal-content/...

ve_sg.accessdoc (SG), Secretaría General de la Comisión Europea

1 Adjuntos

Link: [1]File-List
Link: [2]Edit-Time-Data
Link: [3]themeData
Link: [4]colorSchemeMapping

[5]Ares(2020)4818233 - RE: access to documents request - The Vaccines
Procurement Steering Committee & the Joint Negotiation Team - Gestdem
2020/5436

Sent by ve_sg.accessdoc (SG) <[SG request email]>. All responses have
to be sent to this email address.
Envoyé par ve_sg.accessdoc (SG) <[SG request email]>. Toutes les
réponses doivent être effectuées à cette adresse électronique.

Dear Sir,

Thank you for your e-mail of 15/09/2020. We hereby acknowledge receipt of
your application for access to documents, which was registered on
15/09/2020 under reference number GESTDEM 2020/5436.

In accordance with Regulation (EC) No 1049/2001 regarding public access to
European Parliament, Council and Commission documents, your application
will be handled within 15 working days.

The time limit will expire on 06/10/2020. In case this time limit needs to
be extended, you will be informed in due course.

You have lodged your application via a private third-party website, which
has no link with any institution of the European Union.
Therefore, the European Commission cannot be held accountable for any
technical issues or problems linked to the use of this system.

Please note that the private third party running the AsktheEU.org website
is responsible and accountable for the processing of your personal data
via that website, and not the Commission.
For further information on your rights, please refer to the third party’s
privacy policy.

We understand that the third party running the AsktheEU.org website
usually publishes the content of applicants’ correspondence with the
Commission on that website. This includes the personal data that you may
have communicated to the Commission (e.g. your private postal address).

Similarly, the third party publishes on that website any reply that the
Commission will send to the email address of the applicants generated by
the AsktheEU.org website.

If you do not wish that your correspondence with the Commission is
published on a private third-party website such as AsktheEU.org, you can
provide us with an alternative, private e-mail address for further
correspondence. In that case, the Commission will send all future
electronic correspondence addressed to you only to that private address,
and it will use only that private address to reply to your request. You
should still remain responsible to inform the private third-party website
about this change of how you wish to communicate with, and receive a reply
from, the Commission.

For information on how we process your personal data visit our page
[6]Privacy statement – access to documents.

Yours faithfully,

 

ACCESS TO DOCUMENTS TEAM (GD)

 

[7]cid:image001.png@01D45409.F767C980

European Commission

Secretariat-General

SG C.1

[8][email address]

 

 

mostrar partes citadas

Secretaría General de la Comisión Europea

1 Adjuntos

Dear Mr HOEDEMAN,

             

We refer to your requests both dated 15 September 2020 in which you make a
request for access to documents, both registered on the same date under
the above mentioned reference numbers.

 

Your applications are currently being handled. However, we will not be in
a position to complete the handling of your applications within the time
limit of 15 working days, which expires on 06 October 2020.

 

An extended time limit is needed due to internal consultations and a
thorough analysis of your request.

 

Therefore, we have to extend the time limit with 15 working days in
accordance with Article 7(3) of Regulation (EC) No 1049/2001 regarding
public access to documents. The new time limit expires on 27 October 2020.

 

We apologise for this delay and for any inconvenience this may cause.

 

Yours faithfully,

 

SANTE ACCESS TO DOCUMENTS

[1]cid:image001.gif@01D3FF48.374A49E0
European Commission
Health and Food Safety

 

 

References

Visible links

Dear Secretariat General of the European Commission,

Please pass this on to the person who reviews confirmatory applications.

We are filing the following confirmatory application with regards to our access to documents request 'The Vaccines Procurement Steering Committee & the Joint Negotiation Team' (registered on 15/09/2020 under reference number GESTDEM 2020/5436).

The Commission's deadline for responding to our access to documents request expired on 06 October 2020.

The Commission then extended the time limit with 15 working days. The new time limit expired on 27 October 2020. This is now 10 days ago (!) and we have not heard anything from the Commission about the delayed response.

A full history of our request and all correspondence is available on the Internet at this address: https://www.asktheeu.org/en/request/the_...

Yours faithfully,

Olivier Hoedeman
on behalf of Corporate Europe Observatory (CEO)
Rue d'Edimbourg 26,
1050 Brussels, Belgium
http://www.corporateeurope.org

Secretaría General de la Comisión Europea

Your message has been received by the Transparency Unit of the
Secretariat-General of the European Commission.
Requests for public access to documents are treated on the basis of
[1]Regulation (EC) No 1049/2001 of 30 May 2001 regarding public access to
European Parliament, Council and Commission documents.
The Secretariat-General will reply to your request within 15 working days
upon registration of your request and will duly inform you of the
registration of the request (or of any additional information to be
provided in view of its registration and/or treatment).
 
 
L’unité «Transparence» du secrétariat général de la Commission européenne
a bien reçu votre message.
Les demandes d’accès du public aux documents sont traitées sur la base du
[2]règlement (CE) n° 1049/2001 du 30 mai 2001 relatif à l’accès du public
aux documents du Parlement européen, du Conseil et de la Commission.
Le secrétariat général répondra à votre demande dans un délai de 15 jours
ouvrables à compter de la date d’enregistrement de votre demande, et vous
informera de cet enregistrement (ou vous indiquera toute information
supplémentaire à fournir en vue de l'enregistrement et/ou du traitement de
votre demande).
 
 
Ihre Nachricht ist beim Referat „Transparenz“ des Generalsekretariats der
Europäischen Kommission eingegangen.
Anträge auf Zugang zu Dokumenten werden auf der Grundlage der
[3]Verordnung (EG) Nr. 1049/2001 vom 30. Mai 2001 über den Zugang der
Öffentlichkeit zu Dokumenten des Europäischen Parlaments, des Rates und
der Kommission behandelt.
Das Generalsekretariat beantwortet Ihre Anfrage innerhalb von
15 Arbeitstagen nach deren Registrierung und wird Sie über die
Registrierung Ihres Antrags (oder die Notwendigkeit weiterer Informationen
im Hinblick auf dessen Registrierung und/oder Bearbeitung) unterrichten.
 
 

References

Visible links
1. https://eur-lex.europa.eu/legal-content/...
2. https://eur-lex.europa.eu/legal-content/...
3. https://eur-lex.europa.eu/legal-content/...

ve_sg.accessdoc (SG), Secretaría General de la Comisión Europea

[1]Ares(2020)6427281 - RE: Internal review of access to documents request
- The Vaccines Procurement Steering Committee & the Joint Negotiation Team

Sent by ve_sg.accessdoc (SG) <[SG request email]>. All responses have
to be sent to this email address.
Envoyé par ve_sg.accessdoc (SG) <[SG request email]>. Toutes les
réponses doivent être effectuées à cette adresse électronique.

Dear Sir,

Thank you for your email dated 06/11/2020 by which you request, pursuant
to Regulation No 1049/2001 regarding public access to European Parliament,
Council and Commission documents, a review of the position taken by DG
SANTE in reply to your initial application GESTDEM 2020/5436.

We hereby acknowledge receipt of your confirmatory application for access
to documents which was registered on 06/11/2020 (Ares(2020)6426066).

Your application will be handled within 15 working days (27/11/2020). In
case this time limit needs to be extended, you will be informed in due
course.

Please be informed that the answer to your confirmatory application is a
formal Commission decision that will be notified to you by express
delivery. Thank you for providing your contact phone number, so that the
external delivery service can contact you in case of absence.

Please note that the Commission will not use your phone number for any
other purpose than for informing the delivery service, and that it will
delete it immediately thereafter.

Yours faithfully,

Access to documents team (RC)

mostrar partes citadas

Dear ve_sg.accessdoc (SG),

important clarification: rather than "a review of the position taken by DG SANTE", I want the Commission to act on the excessive delay in responding to my access to documents request application GESTDEM 2020/5436. DG SANTE did not take any position yet, but failed to respond within the deadlines outlined in regulation 1049/2001.

Responding that my "application will be handled within 15 working days (27/11/2020)" only makes things worse (adding yet another three weeks delay before getting a response / receiving the documents).

Yours sincerely,

Olivier Hoedeman
on behalf of
Corporate Europe Observatory (CEO)
Rue d'Edimbourg 26,
1050 Brussels, Belgium

http://www.corporateeurope.org
Tel. +32 (0)2 893 0930

Secretaría General de la Comisión Europea

Your message has been received by the Transparency Unit of the
Secretariat-General of the European Commission.
Requests for public access to documents are treated on the basis of
[1]Regulation (EC) No 1049/2001 of 30 May 2001 regarding public access to
European Parliament, Council and Commission documents.
The Secretariat-General will reply to your request within 15 working days
upon registration of your request and will duly inform you of the
registration of the request (or of any additional information to be
provided in view of its registration and/or treatment).
 
 
L’unité «Transparence» du secrétariat général de la Commission européenne
a bien reçu votre message.
Les demandes d’accès du public aux documents sont traitées sur la base du
[2]règlement (CE) n° 1049/2001 du 30 mai 2001 relatif à l’accès du public
aux documents du Parlement européen, du Conseil et de la Commission.
Le secrétariat général répondra à votre demande dans un délai de 15 jours
ouvrables à compter de la date d’enregistrement de votre demande, et vous
informera de cet enregistrement (ou vous indiquera toute information
supplémentaire à fournir en vue de l'enregistrement et/ou du traitement de
votre demande).
 
 
Ihre Nachricht ist beim Referat „Transparenz“ des Generalsekretariats der
Europäischen Kommission eingegangen.
Anträge auf Zugang zu Dokumenten werden auf der Grundlage der
[3]Verordnung (EG) Nr. 1049/2001 vom 30. Mai 2001 über den Zugang der
Öffentlichkeit zu Dokumenten des Europäischen Parlaments, des Rates und
der Kommission behandelt.
Das Generalsekretariat beantwortet Ihre Anfrage innerhalb von
15 Arbeitstagen nach deren Registrierung und wird Sie über die
Registrierung Ihres Antrags (oder die Notwendigkeit weiterer Informationen
im Hinblick auf dessen Registrierung und/oder Bearbeitung) unterrichten.
 
 

References

Visible links
1. https://eur-lex.europa.eu/legal-content/...
2. https://eur-lex.europa.eu/legal-content/...
3. https://eur-lex.europa.eu/legal-content/...

ve_sg.accessdoc (SG), Secretaría General de la Comisión Europea

1 Adjuntos

Link: [1]File-List
Link: [2]Edit-Time-Data
Link: [3]themeData
Link: [4]colorSchemeMapping

[5]Ares(2020)7142196 - Your confirmatory application for access to
documents under Regulation (EC) No 1049/2001 - GESTDEM 2020-5436 - 1st
holding letter

Sent by ve_sg.accessdoc (SG) <[SG request email]>. All responses have
to be sent to this email address.
Envoyé par ve_sg.accessdoc (SG) <[SG request email]>. Toutes les
réponses doivent être effectuées à cette adresse électronique.

Dear Mr Hoedeman,

We refer to your email of  6 November 2020, registered on the same day, by
which you submitted a confirmatory application in accordance with Article
7(2) of Regulation (EC) No 1049/2001 regarding public access to European
Parliament, Council and Commission documents[6]^[1] ("Regulation (EC) No
1049/2001").

 

Your confirmatory application is currently being handled. Unfortunately,
we have not yet been able to gather all the elements needed to carry out a
full analysis of your request and to take a final decision. Therefore, we
are not in a position to reply to your confirmatory request within the
prescribed time limit which expires on 18 December 2020.

 

We apologise for this delay and for any inconvenience this may cause but
we would like to assure you that we will do our utmost to provide you with
a reply as soon as possible.

 

Yours sincerely,

 

 

María OLIVÁN AVILÉS
Head of Unit

[7]cid:image001.gif@01D13362.41D673C0

European Commission

Secretariat General

Unit C.1 (Transparency, Document Management and Access to Documents)

 

------------------------

[8][1]               Official Journal L 145 of 31.5.2001, p. 43.

References

Visible links
1. file:///tmp/cid:filelist.xml@01D6C4AA.5F70CA00
2. file:///tmp/cid:editdata.mso
3. file:///tmp/~~themedata~~
4. file:///tmp/~~colorschememapping~~
5. https://webgate.ec.testa.eu/Ares/documen...
6. file:///tmp/foiextract20211201-31628-1pdo3xg#_ftn1
8. file:///tmp/foiextract20211201-31628-1pdo3xg#_ftnref1

ve_sg.accessdoc (SG), Secretaría General de la Comisión Europea

1 Adjuntos

Link: [1]File-List
Link: [2]Edit-Time-Data
Link: [3]themeData
Link: [4]colorSchemeMapping

[5]Ares(2020)7726566 - Your confirmatory application for access to
documents under Regulation (EC) No 1049/2001 - GESTDEM 2020/5436 - 2nd
holding letter

Sent by ve_sg.accessdoc (SG) <[SG request email]>. All responses have
to be sent to this email address.
Envoyé par ve_sg.accessdoc (SG) <[SG request email]>. Toutes les
réponses doivent être effectuées à cette adresse électronique.

Dear Mr
Hoedeman,                                                                

We refer to your email of  6 November 2020, registered on the same day, by
which you submitted a confirmatory application in accordance with Article
7(2) of Regulation (EC) No 1049/2001 regarding public access to European
Parliament, Council and Commission documents[6]^[1] ("Regulation (EC) No
1049/2001"). We also refer to our holding letter of 27 November 2020.

 

Your confirmatory application is currently being handled. Unfortunately,
the internal consultations are still ongoing in relation to your
request. Therefore, we are not in a position to reply to your confirmatory
request within the prescribed time limit which expires on 18 December
2020.

 

We apologise for this delay and for any inconvenience this may cause but
we would like to assure you that we will do our utmost to provide you with
a reply as soon as possible.

 

Yours sincerely,

 

 

María OLIVÁN AVILÉS
Head of Unit

[7]cid:image001.gif@01D13362.41D673C0

European Commission

Secretariat General

Unit C.1 (Transparency, Document Management and Access to Documents)

 

------------------------

[8][1]               Official Journal L 145 of 31.5.2001, p. 43.

References

Visible links
1. file:///tmp/cid:filelist.xml@01D6D519.09639C30
2. file:///tmp/cid:editdata.mso
3. file:///tmp/~~themedata~~
4. file:///tmp/~~colorschememapping~~
5. https://webgate.ec.testa.eu/Ares/documen...
6. file:///tmp/foiextract20211201-31628-1o4tsoo#_ftn1
8. file:///tmp/foiextract20211201-31628-1o4tsoo#_ftnref1

Dear Secretariat-General (SG),

on December 18th you informed us that "internal consultations are still ongoing" regarding our access to documents request GESTDEM 2020/5436 and that you "are not in a position to reply" within the prescribed time limit", which expired that same day. You announced that you would reply "as soon as possible." In other words: no specific explanation or justification, no new deadline but an indefinite delay.

Our access to documents request was submitted on September 15th and we have still not received a substantive response, let alone received any of the documents we asked for. This is completely at odds with the Commission's obligations under Regulation 1049/2001 (which has clear deadlines for responding) and constitutes maladministration.

Your handling of our request gives us the impression that the Commission has de facto unilaterally decided that the EU's access to documents legislation does not apply to the covid-19 vaccine deals. Our request outlined very clearly the overriding public interest in the disclosure of the documents.

We are deeply disappointed by the Commission's handling of our request and see no other option than submitting a complaint to the European Ombudsman.

Yours sincerely,

Olivier Hoedeman
on behalf of Corporate Europe Observatory (CEO)
Rue d'Edimbourg 26,
1050 Brussels, Belgium

Sg-Acc-Doc@ec.europa.eu, Secretaría General de la Comisión Europea

Your message has been received by the Transparency Unit of the
Secretariat-General of the European Commission.
Requests for public access to documents are treated on the basis of
[1]Regulation (EC) No 1049/2001 of 30 May 2001 regarding public access to
European Parliament, Council and Commission documents.
The Secretariat-General will reply to your request within 15 working days
upon registration of your request and will duly inform you of the
registration of the request (or of any additional information to be
provided in view of its registration and/or treatment).
 
 
L’unité «Transparence» du secrétariat général de la Commission européenne
a bien reçu votre message.
Les demandes d’accès du public aux documents sont traitées sur la base du
[2]règlement (CE) n° 1049/2001 du 30 mai 2001 relatif à l’accès du public
aux documents du Parlement européen, du Conseil et de la Commission.
Le secrétariat général répondra à votre demande dans un délai de 15 jours
ouvrables à compter de la date d’enregistrement de votre demande, et vous
informera de cet enregistrement (ou vous indiquera toute information
supplémentaire à fournir en vue de l'enregistrement et/ou du traitement de
votre demande).
 
 
Ihre Nachricht ist beim Referat „Transparenz“ des Generalsekretariats der
Europäischen Kommission eingegangen.
Anträge auf Zugang zu Dokumenten werden auf der Grundlage der
[3]Verordnung (EG) Nr. 1049/2001 vom 30. Mai 2001 über den Zugang der
Öffentlichkeit zu Dokumenten des Europäischen Parlaments, des Rates und
der Kommission behandelt.
Das Generalsekretariat beantwortet Ihre Anfrage innerhalb von
15 Arbeitstagen nach deren Registrierung und wird Sie über die
Registrierung Ihres Antrags (oder die Notwendigkeit weiterer Informationen
im Hinblick auf dessen Registrierung und/oder Bearbeitung) unterrichten.
 
 

References

Visible links
1. https://eur-lex.europa.eu/legal-content/...
2. https://eur-lex.europa.eu/legal-content/...
3. https://eur-lex.europa.eu/legal-content/...

Olivier Hoedeman dejó un comentario ()

On January 22nd, the European Ombudsman started investigating the European Commission's secrecy around its Covid-19 vaccine contracts with pharmaceutical companies and the negotiations that shaped these contracts. This inquiry was sparked by complaints filed by Corporate Europe Observatory (CEO) against the Commission's handling of this Freedom of Information (FOI) request, as well as a second FOI request for the disclosure of the Commission's contract with AstraZeneca.

ve_sante.c.3(SANTE), Secretaría General de la Comisión Europea

2 Adjuntos

Dear Mr Hoedeman,

Please find attached document Ares(2021)1844668 from GALLINA Sandra (SANTE) dated 15/03/2021.

Best regards,
SANTE C3 Secretariat

Olivier Hoedeman dejó un comentario ()

On June 3rd, CEO wrote to Sandra Gallina (Director-General for Health and Food Safety in the European Commission) to inquire about the Commission’s lack of follow-up on transparency promises made in the context of the European Ombudsman’s inquiry on public access to documents concerning the purchase of vaccines against COVID-19. The letter is online here: https://corporateeurope.org/sites/defaul...

SANTE ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

76 Adjuntos

Dear Sir,

Please find attached to this reply the first batch of documents concerning your access to documents requests GESTDEM 2020/5436 and GESTDEM 2021/0559.

Kind regards,
SANTE ACCESS TO DOCUMENTS

Olivier Hoedeman dejó un comentario ()

ON June 25th, DG SANTE wrote:

"We would like to inform you that, following the note sent to you on 8th June (Ref. Ares(2021)3769005), DG SANTE completed the assessment of a second batch of documents which have been submitted last week to other Commission's services for consultation.

DG SANTE internal assessment of a third batch of documents is also finalised and ready to be sent to other Commission's services for consultation.

We expect to be able to send you a second reply to your access to documents requests registered under GESTDEM 2020/5436 and GESTDEM 2021/0559 in the course of the following weeks.

We would like to apologise again for the delay."

On October 28th, CEO wrote:

"Dear SANTE ACCESS TO DOCUMENTS,

In June you mentioned that a second reply (presumably with more
documents released) would reach me "in the course of the following weeks".

That is now 4 months ago. Could you inform me why this major delay has occurred and when I can expect the second reply?

Yours sincerely,

Olivier Hoedeman
on behalf of Corporate Europe Observatory (CEO)"

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

1 Adjuntos

Dear Mr. Hoedeman,

In reference to your request, please find attached document Ares(2022)117753 from Mr. Wolfgang Philipp, Director (acting) - Deputy Head of HERA, dated 07/01/2021.

Best regards,

HERA Secretariat

Olivier Hoedeman dejó un comentario ()

Subject: reply to proposal for a 'fair solution
Date: Thu, 20 Jan 2022 17:25:11 +0100
From: Olivier Hoedeman <olivier@corporateeurope.org>
To: HERA-CONSULT-04@ec.europa.eu

Dear Wolfgang Philipp (Acting Deputy Head of HERA),

Thank you for your letter (HERA/KB(2021)8858418) regarding our application for access to documents (GESTDEM2020/5436 and GESTDEM 2021/0559). In your letter you inform us that the application “has now been assigned to the newly established European Health Emergency Preparedness and Response authority (‘HERA’)”. You also make a proposal for a 'fair solution' which is to reduce the scope of our request " to 125 documents out of the 365 documents initially identified". Your suggestion is to grant access "to documents such as agenda, emails, minutes of the Steering Board meetings, and final contracts".

I am afraid we cannot accept the proposal, for the following reasons:

- limiting the scope to cover only documents related to Steering Board meetings and final contracts is seriously at odds with our original request which was for all reports from meetings with pharmaceutical companies and correspondence with these companies about the Advance Purchases Agreements.

- limiting the scope this way is a major step back from what the European Commission has promised the European Ombudsman in the context of the Ombudsman's inquiry last spring (joint cases 85/2021/MIG and 86/2021/MIG). The Ombudsman's decision to close the inquiry was based on the assumption that the Commission would "continue these efforts to deal with the complainant’s access requests promptly and to make swiftly available as many documents as it deems possible, including on its website."

- it is also a major step back compared to was disclosed in the first batch of 80 documents released by DG SANTE in June. This batch included (redacted) correspondence with pharma companies. In your new proposal you appear to want to exclude this from disclosure from now on.

- on June 25th, DG SANTE informed us by email that they had “completed the assessment of a second batch of documents which have been submitted last week to other Commission's services for consultation. DG SANTE internal assessment of a third batch of documents is also finalised and ready to be sent to other Commission's services for consultation. We expect to be able to send you a second reply to your access to documents requests registered under GESTDEM 2020/5436 and GESTDEM 2021/0559 in the course of the following weeks." Unfortunately this second reply has never reached us.
Now, more than six months later, HERA is making a very different proposal, severely limiting the scope of what would be disclosed. The proposal looks like a u-turn compared to previous transparency promises. You refer to “the principle of proportionality” and limiting the work load, but from DG SANTE’s email of June 25th it is clear that the work on assessing at least two other bathes of documents has already been done as this had been sent to other Commission's services for consultation.

I have in December submitted a complaint to the European Ombudsman about the Commission’s failure to fulfil its transparency promises and I will now await the investigation into these matters.

Yours sincerely,
Olivier Hoedeman
on behalf of Corporate Europe Observatory (CEO)

HERA-ACCESS-TO-DOCUMENTS@ec.europa.eu, Secretaría General de la Comisión Europea

1 Adjuntos

  • Attachment

    Reply to Ares 2022 597471 Fair solution proposal GESTDEM 2020 5436 and GESTDEM 2021 0559.pdf

    173K Download View as HTML

 

 

From: HERA ACCESS TO DOCUMENTS <[email address]>
Sent: Friday, February 4, 2022 9:56 AM
To: hoedeman olivier (CORPORATE EUROPE OBSERVATORY)
<[email address]>
Subject: [Re] reply to proposal for a 'fair solution - Ares(2022)821458

 

 

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

73 Adjuntos

Dear Sir/Madam,

Please find enclosed the reply to your access to documents requests 2020/5436 and 2021/0559.

Best regards,

Access to documents team

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

6 Adjuntos

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

1 Adjuntos

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

1 Adjuntos

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

1 Adjuntos

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

17 Adjuntos

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

2 Adjuntos

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

25 Adjuntos

  • Attachment

    113 2 Annex Confidentiality SB Meeting 25 September 2020 NO REDACTION s ok.pdf

    50K Download View as HTML

  • Attachment

    109 Scientific meeting with Moderna 15 July 2020 Redacted s.pdf

    481K Download View as HTML

  • Attachment

    108 Scientific Update by AstraZeneca Representatives Safety and efficacy 15 December 2020 Redacted s.pdf

    496K Download View as HTML

  • Attachment

    94 Scientific Update by CureVac Representatives 3 November 2020 Report and Presentation Redacted s.pdf

    456K Download View as HTML

  • Attachment

    List of documents 4th Batch merged 30 May.pdf

    573K Download View as HTML

  • Attachment

    107 European Commission s advisory panel on COVID 19 Invitation letter and report videoconference 20072020 Ares 2021 1077274 v6 Redacted s ok.pdf

    370K Download View as HTML

  • Attachment

    92 Scientific Update by Sanofi Pasteur Representatives 17 December 2020 Report and Presentation v1 2 Redacted s.pdf

    622K Download View as HTML

  • Attachment

    103 Steering Board Meeting with Experts from the Scientific Board of France Spain and the Netherlands 27 July 2020 Report of the meeting Redacted s.pdf

    604K Download View as HTML

  • Attachment

    93 Scientific Update by CureVac Representatives 17 November 2020 Pre Clinical and Clinical Development Data Update Report and Presentation Redacted s.pdf

    389K Download View as HTML

  • Attachment

    116 1 Draft APA negotiated between AstraZeneca and EvaluationCommittee on 13 08 20 2 email 2 Redacted s ok.pdf

    1.6M Download View as HTML

  • Attachment

    115 Draft APA negotiated between AstraZeneca and the Evaluation Committee on 13 08 20 Redacted s ok.pdf

    415K Download View as HTML

  • Attachment

    99 Scientific Presentation by Johnson Johnson Representatives 4 September 2020 Report and Presentation Redacted s.pdf

    597K Download View as HTML

  • Attachment

    31 Email SB Agenda 11 September 2020 Redacted s.pdf

    230K Download View as HTML

  • Attachment

    100 Scientific Presentation by CureVac Representatives 28 August 2020 Report and Presentation Redacted s.pdf

    481K Download View as HTML

  • Attachment

    107 2 European Commission s advisory panel on COVID 19 Report videoconference 20072020 Redacted s.pdf

    421K Download View as HTML

  • Attachment

    Partially positive fourth batch 2020 5436 and 2021 0559 FINAL 2022 4349699.pdf

    443K Download View as HTML

  • Attachment

    20 SB Minutes 17 August 2020 Redacted s.pdf

    613K Download View as HTML

  • Attachment

    107 1 European Commission s advisory panel on COVID 19 Invitation letter Redacted s.pdf

    469K Download View as HTML

  • Attachment

    98 Scientific Presentation by Sanofi GSK Representatives 9 September 2020 Report and Presentation Redacted s.pdf

    511K Download View as HTML

  • Attachment

    20 1 pro rata adjusted EUROSTAT Redacted s.pdf

    243K Download View as HTML

  • Attachment

    97 Scientific Presentation by CureVac Representatives 28 September 2020 Report and Presentation Redacted s.pdf

    612K Download View as HTML

  • Attachment

    96 Follow up Discussion to the Scientific Presentation by CureVac Representatives 7 October 2020 Redacted s.pdf

    388K Download View as HTML

  • Attachment

    6 SB Minutes 3 July Redacted s.pdf

    564K Download View as HTML

  • Attachment

    91 Scientific Presentation by AstraZeneca Representatives 5 August 2020 Report and Presentation SAURE II v2 Redacted s.pdf

    680K Download View as HTML

  • Attachment

    31 1 Agenda SB Minutes 11 September 2020 Redacted s.pdf

    41K Download View as HTML

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

58 Adjuntos

  • Attachment

    136 follow up questionnaire sent to Astra Zeneca Redacted s.pdf

    67K Download View as HTML

  • Attachment

    180 Draft Advanced Purchase Agreement negotiated between J J and the Evaluation Committee 28 09 2020 2 Redacted s ok.pdf

    275K Download View as HTML

  • Attachment

    179 Draft Advanced Purchase Agreement negotiated between J J and the Evaluation Committee 25 09 2020 2 Redacted s ok.pdf

    292K Download View as HTML

  • Attachment

    117 1 AstraZeneca COVID 19 Vaccine Update on developments sent to the European Commission email rtf Redacted s ok.pdf

    293K Download View as HTML

  • Attachment

    165 CALL FOR TENDERS SANTE2020C3043 OFFER email 2 of 3 ARES 2021 340593 redacted s.pdf

    104K Download View as HTML

  • Attachment

    163 Tender submission in 3 emails ARES 2021 340523 redacted s.pdf

    77K Download View as HTML

  • Attachment

    137 skype meeting with Astra Zeneca 14052020 vaccines Redacted s.pdf

    526K Download View as HTML

  • Attachment

    136 1 Email follow up questionnaire sent to Astra Zeneca Redacted s.pdf

    95K Download View as HTML

  • Attachment

    118 AW Draft Term Sheet for Supply of AstraZeneca COVID 19 vaccine AZD 1222 in Europe com E mail 2 Redacted s ok.pdf

    200K Download View as HTML

  • Attachment

    117 AstraZeneca COVID 19 Vaccine Update on developments sent to the European Commission Redacted s ok.pdf

    706K Download View as HTML

  • Attachment

    186 Jansen J J COVID 19 vaccine proposal to the EC 1 call 6 05 2020 2 Redacted s ok.pdf

    542K Download View as HTML

  • Attachment

    133 1 Commission IR 2021111 of 29 Jan 2021 Regulation.pdf

    922K Download View as HTML

  • Attachment

    185 Jansen J J response to the questionnaire consulted 200506 JVx COVID19 vaccine EC final CLEAN 2 Redacted s ok.pdf

    555K Download View as HTML

  • Attachment

    133 Commission IR 2021111 of 29 Jan 2021 Redacted s.pdf

    194K Download View as HTML

  • Attachment

    185 1 Jansen J J response to the questionnaire 2 Redacted s ok.pdf

    123K Download View as HTML

  • Attachment

    188 6 Jansen J J COVID 19 vaccine proposal to the EC 3 call 10 06 2020 Redacted s.pdf

    483K Download View as HTML

  • Attachment

    187 email 5 Janssen J J COVID 19 vaccine proposal to the EC 2 Redacted s.pdf

    47K Download View as HTML

  • Attachment

    126 Call for tenders SANTE2020C3037.pdf

    328K Download View as HTML

  • Attachment

    183 Draft APA negotiated between J J and the Evaluation Committee technical 06 10 2020 rep 2 Redacted s ok.pdf

    149K Download View as HTML

  • Attachment

    122 RE Draft Term Sheet for Supply of AstraZeneca COVID 19 vaccine AZD 1222 in Europe comments JNT 3 FR Redacted s ok.pdf

    427K Download View as HTML

  • Attachment

    182 Draft APA negotiated between J J and the Evaluation Committee technical 02 10 2020 2 Redacted s ok.pdf

    1.2M Download View as HTML

  • Attachment

    126 1 Call for tenders SANTE2020C3037 for the development production priority purchasing options and supply Redacted s ok.pdf

    5.0M Download View as HTML

  • Attachment

    126 Call for tenders SANTE2020C3037 for the development production priority purchasing options and supply email rtf Redacted s ok.pdf

    61K Download View as HTML

  • Attachment

    184 Janssen J J Expression of Intrest to the EC re COVID 19 vaccine 2 Redacted s ok.pdf

    345K Download View as HTML

  • Attachment

    121 Re URGENT info about suspension of clinical trials for COVID 19 vaccine email Redacted s ok.pdf

    313K Download View as HTML

  • Attachment

    192 email 10 Jansen J J COVID 19 vaccine proposal to the EC and EU4 5 Redacted s.pdf

    49K Download View as HTML

  • Attachment

    171 Notification letter ARES 2021 1090683 redacted s.pdf

    59K Download View as HTML

  • Attachment

    120 Follow up AZ EC exploratory meeting for consultation email rtf Redacted s ok.pdf

    230K Download View as HTML

  • Attachment

    191 email 9 Draft term sheet discussed with Jansen J J at the Joint Negotiation Team during the exploratory talks on 17 06 2020 Redacted s.pdf

    71K Download View as HTML

  • Attachment

    170 Tender submission ARES 2021 471003 redacted s.pdf

    72K Download View as HTML

  • Attachment

    190 Ares 2021 133223 email 8 Draft term sheet discussed with Jansen JJ at JNT during the exploratory talks on 11 06 2020 2 Redacted s ok.pdf

    368K Download View as HTML

  • Attachment

    169 Invitation to tender ARES 2021 312233 redacted s.pdf

    55K Download View as HTML

  • Attachment

    167 Notification Letter ARES 2021 6801133 redacted s.pdf

    65K Download View as HTML

  • Attachment

    193 email 11 Draft term sheet discussed with Jansen J J at the Joint Negotiation Team during the exploratory talks on 10 08 2020 Redacted s.pdf

    427K Download View as HTML

  • Attachment

    172 Notification Letter sent to Pfizer BNT informing of the outcome of the award procedure ARES 2021 1092982 redacted s.pdf

    43K Download View as HTML

  • Attachment

    129 Notification letter SANTE2020C3037 Development production priority purchasing options and supply of COVID 19 Redacted s.pdf

    43K Download View as HTML

  • Attachment

    128 SANTE2020C3037 Notification Letter Call for tenders for the development production priori Redacted s ok.pdf

    69K Download View as HTML

  • Attachment

    189 email 7 Jansen J J COVID 19 vaccine proposal to the EC 4 follow up call 10 06 2020 Redacted s.pdf

    58K Download View as HTML

  • Attachment

    130 SARS CoV 2 Vaccine AZD1222 Progress Report 19 January 2021.pdf

    218K Download View as HTML

  • Attachment

    176 Draft Advanced Purchase Agreement negotiated between J J and the Evaluation Committee technical 04 09 2020 redacted s ok.pdf

    57K Download View as HTML

  • Attachment

    198 Follow up questionnaire sent to Johnson Johnson Janssen.pdf

    112K Download View as HTML

  • Attachment

    197 1 Notification letter SANTE2020C3047 Development production priority purchasing options and supply of COVID 19 redacted s.pdf

    58K Download View as HTML

  • Attachment

    126 2 Call for tenders SANTE2020C3037 for the development production priority purchasing Annex 6 Financial offer Redacted s ok.pdf

    84K Download View as HTML

  • Attachment

    178 Draft Advanced Purchase Agreement negotiated between J J and the Evaluation Committee 18 09 2020 2 Redacted s ok.pdf

    272K Download View as HTML

  • Attachment

    177 Draft APA negotiated between J J and the Evaluation Committee 15 09 2020 2 Redacted s ok.pdf

    75K Download View as HTML

  • Attachment

    196 SANTE2020C3047 Notification Letter Call for tenders for the development production priority purchasing options Ares 2020 5389787 redacted s.pdf

    59K Download View as HTML

  • Attachment

    131 MHRA Public Assessment Report AZ Covid 19 Vaccine email Redacted s ok.pdf

    72K Download View as HTML

  • Attachment

    194 Call for tenders SANTE2020C3047 for the development production priority purchasing options and supply of COVID 19 ARES 2021 312329 redacted s.pdf

    50K Download View as HTML

  • Attachment

    131 MHRA Public Assessment Report AZ Covid 19 Vaccine.pdf

    218K Download View as HTML

  • Attachment

    173 Advance purchase agreement signed by Pfizer BNT in 2 emails Ares 2021 1366893 redacted s.pdf

    192K Download View as HTML

  • Attachment

    173 Advance purchase agreement signed by Pfizer BNT in 2 emails ARES 2021 1366751 redacted s.pdf

    190K Download View as HTML

  • Attachment

    197 Notification letter SANTE2020C3047 Development production priority purchasing options and supply of COVID 19 Ares 2021 340726 redacted s.pdf

    45K Download View as HTML

  • Attachment

    131 1 FD tbc UKPAR COVID 19 Vaccine AstraZeneca 05 01 2021 pdf.pdf

    1.6M Download View as HTML

  • Attachment

    200 email Report from the TC with J J on COVID 19 Vaccine 2 Redacted s ok.pdf

    693K Download View as HTML

  • Attachment

    130 2 Email rtf SARS CoV 2 Vaccine AZD1222 Progress Report 19 January 202 Redacted s.pdf

    73K Download View as HTML

  • Attachment

    199 email skype meeting with Johnson Johnson Janssen vaccine 06052020 2 Redacted s.pdf

    561K Download View as HTML

  • Attachment

    130 1 FD tbcUKPAR COVID 19 Vaccine AstraZeneca 05 01 2021 RED.pdf

    1.6M Download View as HTML

  • Attachment

    198 Follow up questionnaire sent to Johnson Johnson Janssen 2 Redacted s ok.pdf

    95K Download View as HTML

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

85 Adjuntos

  • Attachment

    251 1 RE Meeting of the Evaluation Committee with Moderna today 15 02 at 21 00 marked Ares 2021 1639274 Redacted s.pdf

    325K Download View as HTML

  • Attachment

    213 1 Draft APA negotiated between Moderna and the Evaluation Committee technical on 29 06 2020 Redacted s.pdf

    666K Download View as HTML

  • Attachment

    272 CureVac Proposal to the EC re COVID 19 vaccine follow up email rtf Redacted s ok.pdf

    118K Download View as HTML

  • Attachment

    250 RE Draft PA marked PA Moderna Redacted PB Redacted s.pdf

    235K Download View as HTML

  • Attachment

    211 email Johnson Johnson COVID 19 treatment development update 2 Redacted s.pdf

    162K Download View as HTML

  • Attachment

    253 Notification Letter Ares 2021 1336686 redacted s.pdf

    59K Download View as HTML

  • Attachment

    210 email Johnson Johnson COVID 19 vaccine development update launch of Phase 3 clinical trials 2 Redacted s.pdf

    154K Download View as HTML

  • Attachment

    225 after consultation Email 13 Draft APA negotiated between Moderna and the Evaluation Committ Redacted s.pdf

    345K Download View as HTML

  • Attachment

    252 RE SANTE 2021 C3 010 Meeting of the Evaluation Committee with Mode Redacted s.pdf

    628K Download View as HTML

  • Attachment

    273 CureVac draft Term Sheet discussed with the JNT 200616 CureVac AG EC Final SENT Redacted s ok.pdf

    173K Download View as HTML

  • Attachment

    215 Draft APA negotiated between Moderna and the Evaluation Committee technical 12 11 2020 Redacted s.pdf

    80K Download View as HTML

  • Attachment

    271 1 CureVac Proposal to the EC re COVID 19 vaccine email rtf Redacted s ok.pdf

    68K Download View as HTML

  • Attachment

    214 Draft APA negotiated between Moderna and the Evaluation Committee on 04 11 2020 4 pm Redacted s.pdf

    52K Download View as HTML

  • Attachment

    271 CureVac Proposal to the EC re COVID 19 vaccine CureVac AG Letter to the European Commission Final pdf 1 Redacted s ok.pdf

    133K Download View as HTML

  • Attachment

    269 CureVac Expression of Interest to the EC re COVID 19 vaccine feedback EIB mail rtf Redacted s ok.pdf

    117K Download View as HTML

  • Attachment

    239 8 after consultation Moderna draft Term Sheet discussed with the JNT clauses 20 08 Redacted s.pdf

    78K Download View as HTML

  • Attachment

    268 CureVac Expression of Interest to the EC re COVID 19 vaccine call 07 05 2020 email rtf Redacted s ok.pdf

    168K Download View as HTML

  • Attachment

    228 Answer to question 1 Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5069081 redacted s.pdf

    86K Download View as HTML

  • Attachment

    247 Tender submission Ares 2021 1012684 redacted s.pdf

    71K Download View as HTML

  • Attachment

    227 Question 1 in scope of Invitation to tender for procedure SANTE 2020C3054 Moderna Ares 2020 5069122 redacted s.pdf

    73K Download View as HTML

  • Attachment

    240 7 after consultationModerna draft Term Sheet discussed with the JNT clause 14 08 Redacted s.pdf

    126K Download View as HTML

  • Attachment

    226 after consultation Email 14 Draft APA negotiated between Moderna and the Evaluation Committ Redacted s.pdf

    1018K Download View as HTML

  • Attachment

    267 Draft APA negotiated between CureVac and the Evaluation Committee technical on 24 11 2020 email rtf Fully Redacted s ok.pdf

    249K Download View as HTML

  • Attachment

    282 CureVac with the Joint Negotiation Team L I clause final 19 08 2020 email rtf Redacted s ok.pdf

    501K Download View as HTML

  • Attachment

    281 CureVac with the JNT L I clause pre final 19 08 2020 email rtf Redacted s ok.pdf

    134K Download View as HTML

  • Attachment

    218 1 after consultation6 Draft APA negotiated between Moderna and the Evaluation Committe Redacted s.pdf

    910K Download View as HTML

  • Attachment

    237 Notification letter SANTE2020C3054 Development production priority purchasing options and supply of COVID 19 Ares 2021 340640 redacted s.pdf

    46K Download View as HTML

  • Attachment

    217 5 Draft APA negotiated between Moderna and the Evaluation Committe Redacted s.pdf

    795K Download View as HTML

  • Attachment

    244 1 Moderna revised proposal 10 07 2020 Moderna EU positioning overview 07102020 AME Redacted s.pdf

    191K Download View as HTML

  • Attachment

    287 Answer to question 1 3 Invitation to tender for procedure SANTE2020C3054 Curevac Ares 2020 5095255 redacted s.pdf

    92K Download View as HTML

  • Attachment

    216 4 after consultation Draft APA negotiated between Moderna and the Evaluation Committe Redacted s.pdf

    633K Download View as HTML

  • Attachment

    246 Invitation to tender SANTE2021C3010 Ares 2021 893598 redacted s.pdf

    55K Download View as HTML

  • Attachment

    244 Moderna revised proposal 10 07 2020 Redacted PB s.pdf

    117K Download View as HTML

  • Attachment

    229 Question 2 in scope of Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5069065 redacted s.pdf

    71K Download View as HTML

  • Attachment

    284 Question 1 in scope of Invitation to tender for procedure SANTE 2020C3049 Curevac Ares 2020 5095417 redacted s.pdf

    43K Download View as HTML

  • Attachment

    283 CureVac investigational brochure IB for COVID 19 vaccine email rtf Redacted s ok.pdf

    328K Download View as HTML

  • Attachment

    220 Draft APA negotiated between Moderna and the Evaluation Committee model annex on 19 11 2020 Email Redacted s.pdf

    414K Download View as HTML

  • Attachment

    238 Moderna info on EMA submission timeline for mRNA1273 02 08 2020 Redacted s.pdf

    171K Download View as HTML

  • Attachment

    286 Question 3 in scope of Invitation to tender for procedure SANTE 2020C3049 Curevac Ares 2020 5097658 redacted s.pdf

    81K Download View as HTML

  • Attachment

    219 Email 7 Draft APA negotiated between Moderna and the Evaluation Committe Redacted s.pdf

    662K Download View as HTML

  • Attachment

    237 1 Notification letter SANTE2020C3054 Development production priority purchasing options and supply of COVID 19 Ares 2021 340640 redacted s.pdf

    64K Download View as HTML

  • Attachment

    285 Question 2 in scope of Invitation to tender for procedure SANTE 2020C3049 Curevac Ares 2020 5097658 redacted s.pdf

    44K Download View as HTML

  • Attachment

    264 CureVac Scientific presentation to Member States on 28 09 2020 email rtf Fully Redacted s ok.pdf

    64K Download View as HTML

  • Attachment

    263 1 PreREADS CureVac Scientific presentation to Member States on 28 09 2020 email CureVac Fully Redacted s ok.pdf

    480K Download View as HTML

  • Attachment

    276 2 CureVac with the Joint Negotiation Team 28 07 2020 email rtf Redacted s ok.pdf

    101K Download View as HTML

  • Attachment

    276 1 CureVac with the Joint Negotiation Team 28 07 2020 135 Redacted s ok.pdf

    425K Download View as HTML

  • Attachment

    241 6 after consultationModerna draft Term Sheet discussed with the JNT 11 08 2020 marke Redacted s.pdf

    204K Download View as HTML

  • Attachment

    265 CureVac Scientific presentation to Member States on 3 11 2020 email rtf Fully Redacted s ok.pdf

    53K Download View as HTML

  • Attachment

    266 Draft APA negotiated between CureVac and the Evaluation Committee on 12 11 2020 email rtf Redacted s ok.pdf

    110K Download View as HTML

  • Attachment

    279 CureVac with the Joint Negotiation Team L I clause 17 08 2020 email rtf Redacted s ok.pdf

    333K Download View as HTML

  • Attachment

    278 CureVac COVID 19 vaccine update and current data from clinical trials 17 08 2020 137 2 Redacted s ok.pdf

    486K Download View as HTML

  • Attachment

    201 Summary J J TC on COVID 19 Vaccine Redacted s.pdf

    1.2M Download View as HTML

  • Attachment

    229 1 Questions in scope of Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5069065 redacted s.pdf

    81K Download View as HTML

  • Attachment

    243 3 after consultation Reply to Moderna proposal by the Commission SB feedback 22 07 Redacted s.pdf

    113K Download View as HTML

  • Attachment

    241 1 RE Presentation of new data concerning mRNA marked Moderna Redact Redacted s.pdf

    810K Download View as HTML

  • Attachment

    280 CureVac with the Joint Negotiation Team 18 08 2020 email rtf Redacted s ok.pdf

    51K Download View as HTML

  • Attachment

    221 after consultation Email 9 Draft APA negotiated between Moderna and the Evaluation Committe Redacted s.pdf

    1.0M Download View as HTML

  • Attachment

    275 CureVac draft Term Sheet Joint Negotiation Team comments EC 08 07 2020 2 email rtf Redacted s ok.pdf

    303K Download View as HTML

  • Attachment

    254 Notification Letter sent to Moderna informing of the outcome of the award procedure Ares 2021 1342678 redacted s.pdf

    46K Download View as HTML

  • Attachment

    234 Call for tenders SANTE2020C3054 for the development production priority purchasing options and supply of COVID 19 Ares 2021 312291 redacted s.pdf

    53K Download View as HTML

  • Attachment

    274 CureVac draft Term Sheet Joint Negotiation Team comments FR 08 07 2020 email rtf Redacted s ok.pdf

    257K Download View as HTML

  • Attachment

    233 Answer to question 3 Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5095409 redacted s.pdf

    92K Download View as HTML

  • Attachment

    273 1 CureVac draft discussed with the Joint Negotiation Team first draft 16 06 2020 email rtf Redacted s ok.pdf

    586K Download View as HTML

  • Attachment

    204 email Study Johnson and Johnson vaccine successfully prevents COVID 19 infections in monkeys 2 Redacted s.pdf

    232K Download View as HTML

  • Attachment

    255 Meeting of the Evaluation Committee with Moderna 12 02 2021 at 16 00 Redacted s.pdf

    52K Download View as HTML

  • Attachment

    203 BTO 11 March Mtg J J and SANTE Redacted s.pdf

    184K Download View as HTML

  • Attachment

    263 PreREADS CureVac Scientific presentation to Member States on 28 09 2020 Ares 2021 275043 Redacted s ok.pdf

    1.1M Download View as HTML

  • Attachment

    262 Draft APA negotiated between CureVac and the Evaluation Committee technical 25 09 202 email rtf Fully Redacted s ok.pdf

    73K Download View as HTML

  • Attachment

    232 Question 3 in scope of Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5095385 redacted s.pdf

    69K Download View as HTML

  • Attachment

    209 RE J J Announces a Lead Vaccine Candidate for COVID 19 Redacted s.pdf

    286K Download View as HTML

  • Attachment

    231 Complement Answer to question 2 Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5095249 redacted s.pdf

    178K Download View as HTML

  • Attachment

    207 and 208 Re Johnson Johnson announces a Lead Vaccine Candidate for COVID 19 Redacted s.pdf

    687K Download View as HTML

  • Attachment

    230 Answer to question 2 Invitation to tender for procedure SANTE2020C3054 Moderna Ares 2020 5069108 redacted s.pdf

    156K Download View as HTML

  • Attachment

    206 JJ Joins Industry Partners to Launch the 1 Billion AMR Action Fund 2 Redacted s.pdf

    155K Download View as HTML

  • Attachment

    202 RE Summary J J TC on COVID 19 Vaccine rep 2 Redacted s.pdf

    210K Download View as HTML

  • Attachment

    248 request for clarifications and missing documents call or tenders SANTE2021C3010 Ares 2021 1153333 redacted s.pdf

    43K Download View as HTML

  • Attachment

    270 3 CureVac response to the questionnaire email rtf Redacted s ok.pdf

    142K Download View as HTML

  • Attachment

    270 2 CureVac response to the questionnaire 20200519 Meeting with the EC Redacted s ok.pdf

    227K Download View as HTML

  • Attachment

    249 clarifications and missing documents call or tenders SANTE2021C3010 Ares 2021 1255168 redacted s.pdf

    110K Download View as HTML

  • Attachment

    224 after consultation Email 12 Draft APA negotiated between Moderna and the Evaluation Committ Redacted s.pdf

    548K Download View as HTML

  • Attachment

    236 SANTE2020C3054 Notification Letter Call for tenders for the development production priority purchasing options Ares 2020 7207031 redacted s.pdf

    63K Download View as HTML

  • Attachment

    223 after consultation Email 11 Draft APA negotiated between Moderna and the Evaluation Committ Redacted s.pdf

    960K Download View as HTML

  • Attachment

    288 Answer to question 2 Invitation to tender for procedure SANTE2020C3054 Curevac Ares 2020 5095206 redacted s.pdf

    56K Download View as HTML

  • Attachment

    222 after consultation Email 10 Draft APA negotiated between Moderna and the Evaluation Committ Redacted s.pdf

    921K Download View as HTML

  • Attachment

    270 CureVac response to the questionnaire 8052020 FINAL CLEAN 1 Redacted s ok.pdf

    2.2M Download View as HTML

HERA ACCESS TO DOCUMENTS, Secretaría General de la Comisión Europea

75 Adjuntos

  • Attachment

    346 2 Invitation to tender Annex 6 Financial offer xlsx pdf Redacted s.pdf

    92K Download View as HTML

  • Attachment

    316 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 11 09 20 3 Sanofi Internal Redacted s.pdf

    56K Download View as HTML

  • Attachment

    347 Q1 RE Call for tenders SANTE2020C3087 for the development production priority purchasing options and supply of Redacted s.pdf

    122K Download View as HTML

  • Attachment

    339 Novavax exploratory talks outcome 11 12 2020 Redacted s.pdf

    92K Download View as HTML

  • Attachment

    366 Overview contacts with other companies for Board 200730 Redacted s.pdf

    94K Download View as HTML

  • Attachment

    315 Email 8 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 11 09 20 2 Redacted s.pdf

    1.2M Download View as HTML

  • Attachment

    341 Novavax exploratory talks with JNT 6 12 2020 email Redacted s.pdf

    49K Download View as HTML

  • Attachment

    340 Novavax exploratory talks with JNT Indemnity Liability Comments 5 11 2020 Redacted s.pdf

    514K Download View as HTML

  • Attachment

    321 Sanofi GSK proposed options on post approval studies 08 09 20 Redacted s.pdf

    52K Download View as HTML

  • Attachment

    365 Meeting of the Evaluation Committee with Novavax Thursday 04 03 21 at 4 30 pm 2 Redacted s.pdf

    258K Download View as HTML

  • Attachment

    321 1 Sanofi GSK proposed options on post approval studies 08 09 20 Redacted s.pdf

    58K Download View as HTML

  • Attachment

    290 Tender submission see 8 below entries submission in 8 emails Ares 2021 399673 redacted s.pdf

    67K Download View as HTML

  • Attachment

    317 Sanofi 10 Draft APA negotiated between SanofiGSK and the Evaluation Committee 14 09 20 Redacted s.pdf

    1.3M Download View as HTML

  • Attachment

    345 Novavax exploratory talks with JNT Idemnification 19 09 2020 Redacted s.pdf

    54K Download View as HTML

  • Attachment

    289 Call for tenders SANTE2020C3049 for the development production priority purchasing options and supply of COVID 19 Ares 2021 312310 redacted s.pdf

    56K Download View as HTML

  • Attachment

    320 Sanofi GSK COVID19 vaccine Progress report 26 10 20 Redacted s.pdf

    68K Download View as HTML

  • Attachment

    343 Novavax exploratory talks with JNT 25 08 2020 email Redacted s.pdf

    47K Download View as HTML

  • Attachment

    318 and 319 Scan of a signed version of the APA sent to Sanofi GSK 25 09 20 Redacted s.pdf

    829K Download View as HTML

  • Attachment

    344 Novavax exploratory talks with JNT 26 08 2020 email Redacted s.pdf

    46K Download View as HTML

  • Attachment

    342 Novavax exploratory talks with JNT 9 12 2020 email Redacted s.pdf

    39K Download View as HTML

  • Attachment

    367 Overview contacts with other companies 200714 xlsx Redacted s.pdf

    90K Download View as HTML

  • Attachment

    302 skype meeting with CureVac vaccine 07 05 2020.pdf

    748K Download View as HTML

  • Attachment

    332 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 22 07 20.pdf

    107K Download View as HTML

  • Attachment

    301 questionnaire CureVac 12052020 pdf 1.pdf

    543K Download View as HTML

  • Attachment

    334 Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID 19 Redacted s.pdf

    180K Download View as HTML

  • Attachment

    302 skype meeting with CureVac vaccine 07 05 2020 Redacted s.pdf

    397K Download View as HTML

  • Attachment

    360 RE CALL FOR TENDERS SANTE2020C3087 New Subcontractors Redacted s.pdf

    81K Download View as HTML

  • Attachment

    333 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 29 07 20 Redacted s.pdf

    128K Download View as HTML

  • Attachment

    313 Email 6 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 10 09 20 Redacted s.pdf

    820K Download View as HTML

  • Attachment

    311 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 04 09 20 Redacted s.pdf

    107K Download View as HTML

  • Attachment

    338 skype meeting with GSK 12052020 vaccines Redacted s.pdf

    527K Download View as HTML

  • Attachment

    359 RE CALL FOR TENDERS SANTE2020C3087 OFFER request 1 follow up answer Redacted s.pdf

    204K Download View as HTML

  • Attachment

    300 Notification letter SANTE2020C3049 Development production priority purchasing options and supply of COVID 19 Ares 2021 340610 redacted s.pdf

    46K Download View as HTML

  • Attachment

    299 SANTE2020C3049 Notification Letter Call for tenders for the development production priority purchasing options Ares 2020 6962203 redacted s.pdf

    62K Download View as HTML

  • Attachment

    314 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 11 09 20 Sanofi Internal Redacted s.pdf

    68K Download View as HTML

  • Attachment

    336 1 meeting with SANOFI on APIS on 2 04 bto 2 Redacted s.pdf

    96K Download View as HTML

  • Attachment

    335 Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID 19 redacted s.pdf

    179K Download View as HTML

  • Attachment

    310 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 03 09 20 Redacted s.pdf

    49K Download View as HTML

  • Attachment

    337 Follow up questionnaire sent to GSK redacted s.pdf

    95K Download View as HTML

  • Attachment

    363 Novavax investigator brochure Redacted s.pdf

    43K Download View as HTML

  • Attachment

    336 Ares 2020 2270849 meeting with SANOFI on APIS on 2 04 bto 2 Redacted s.pdf

    96K Download View as HTML

  • Attachment

    364 Meeting of the Evaluation Committee with Novavax Thursday 04 03 21 at 4 30 pm Redacted s.pdf

    173K Download View as HTML

  • Attachment

    361 Novavax EU Commission Draft APA 03022021 Redacted s.pdf

    61K Download View as HTML

  • Attachment

    362 Novavax EU Commission Draft APA 14112020 Redacted s.pdf

    64K Download View as HTML

  • Attachment

    327 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 22 06 20 Redacted s.pdf

    153K Download View as HTML

  • Attachment

    329 Sanofi GSK presentation exploratory talks 25 06 20 redacted s.pdf

    573K Download View as HTML

  • Attachment

    351 Draft APA based on your tender Redacted s.pdf

    75K Download View as HTML

  • Attachment

    328 Sanofi GSK pre reads exploratory talks 24 06 20 redacted s.pdf

    83K Download View as HTML

  • Attachment

    352 RE CALL FOR TENDERS SANTE2020C3087 OFFER request 1 Redacted s.pdf

    98K Download View as HTML

  • Attachment

    309 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 27 08 2020 App Redacted s.pdf

    137K Download View as HTML

  • Attachment

    308 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 27 08 20 Sanofi Redacted s.pdf

    764K Download View as HTML

  • Attachment

    331 1 Email 8 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 10 07 20 Redacted s.pdf

    746K Download View as HTML

  • Attachment

    350 Tender submission Redacted s.pdf

    60K Download View as HTML

  • Attachment

    330 2 Answers to your questions list guiding you in the Term Sheet version 2 Redacted s.pdf

    168K Download View as HTML

  • Attachment

    358 RE CALL FOR TENDERS SANTE2020C3087 OFFER request 1 follow up Redacted s.pdf

    539K Download View as HTML

  • Attachment

    330 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 29 06 20 Redacted s.pdf

    59K Download View as HTML

  • Attachment

    307 Notification letter SANTE2020C3042 Development production priority purchasing options and supply of COVID 19 Ares 2021 340742 redacted s.pdf

    48K Download View as HTML

  • Attachment

    331 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 10 07 20Redacted s.pdf

    53K Download View as HTML

  • Attachment

    356 RE CALL FOR TENDERS SANTE2020C3087 OFFER request 3 Redacted s.pdf

    952K Download View as HTML

  • Attachment

    306 SANTE2020C3042 Notification Letter Call for tenders for the development production priority purchasing options Ares 2020 4819456 redacted s.pdf

    63K Download View as HTML

  • Attachment

    330 3 Cover Letter explaining the principles of the revised Term Sheet version 2 Redacted s.pdf

    140K Download View as HTML

  • Attachment

    357 RE CALL FOR TENDERS SANTE2020C3087 OFFER answer 3 Redacted s.pdf

    276K Download View as HTML

  • Attachment

    353 1 email Call for tender SANTE 2020 C3 087 Redacted s.pdf

    401K Download View as HTML

  • Attachment

    324 Sanofi response to the questionnaire 19 05 20 Email Redacted s.pdf

    231K Download View as HTML

  • Attachment

    355 RE CALL FOR TENDERS SANTE2020C3087 OFFER answer 2 Redacted s.pdf

    825K Download View as HTML

  • Attachment

    323 Summary of the meeting with Sanofi 26 October 1200 1245 pm via WebEx Redacted s.pdf

    361K Download View as HTML

  • Attachment

    346 Invitation to tender SANTE2020C3087 Redacted s.pdf

    70K Download View as HTML

  • Attachment

    322 Ares 2021 745642 Sanofi GSK Scientific technical presentation Sanofi GSK 09 09 20 Redacted s.pdf

    237K Download View as HTML

  • Attachment

    346 1 Invitation to tender Tender Specifications Vaccins COVID19 5 pdf Redacted s.pdf

    5.6M Download View as HTML

  • Attachment

    326 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 12 06 20 Redacted s.pdf

    86K Download View as HTML

  • Attachment

    325 GSK response to the questionnaire 21 05 20 Redacted s.pdf

    322K Download View as HTML

  • Attachment

    324 1 Sanofi response to the questionnaire 19 05 20 Redacted s.pdf

    210K Download View as HTML

  • Attachment

    304 Call for tenders SANTE2020C3042 for the development production priority purchasing options and supply of COVID 19 Ares 2021 312411 redacted s.pdf

    53K Download View as HTML

  • Attachment

    349 Answer to Q1 part 2 RE SANTE2020C3087 question on deadline Redacted s.pdf

    826K Download View as HTML

  • Attachment

    348 Answer to Q1 part 1 Redacted s.pdf

    603K Download View as HTML

Sg-Acc-Doc@ec.europa.eu, Secretaría General de la Comisión Europea

2 Adjuntos

Dear Sir,

 

Please find attached an advance copy of the reply to your confirmatory
request for access to documents registered under the number GESTDEM
2020/5436.

 

Yours faithfully,

 

Access to documents team (cr)
SG.C.1
Transparency
[1]cid:image004.gif@01D4F9CD.7B22B0F0

 

 

References

Visible links

No sabemos si la última respuesta a esta solicitud contiene información o no – si eres Olivier Hoedeman por favor abre una sesión y háznoslo saber.